• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Sohi Mohsen exercised 4,110 units of Ordinary Shares at a strike of $64.05 and sold $994,456 worth of Ordinary Shares (4,110 units at $241.96) (SEC Form 4)

    8/12/25 5:28:02 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sohi Mohsen

    (Last) (First) (Middle)
    70 SIR JOHN ROGERSON'S QUAY

    (Street)
    DUBLIN 2 L2 D02 R296

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    STERIS plc [ STE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 08/11/2025 M 4,110 A $64.05 26,471 D
    Ordinary Shares 08/11/2025 S 4,110 D $241.96(1) 22,361 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Director Stock Option (right to buy) $242.85 08/08/2025 A 2,226 (2) 08/08/2035 Ordinary Shares 2,226 $0 2,226 D
    Career Restricted Stock Units (3) 08/08/2025 A 772 (4) (4) Ordinary Shares 772 $0 7,244 D
    Career Restricted Stock Units (3) 08/08/2025 A 506 (4) (4) Ordinary Shares 506 $242.85(5) 7,750 D
    Director Stock Option (right to buy) $64.05 08/11/2025 M 4,110 (6) 08/31/2025 Ordinary Shares 4,110 $0 0 D
    Explanation of Responses:
    1. Price reflects a weighted average sale price for multiple transactions ranging from $241.36 to $242.295 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    2. These nonqualified stock options are fully vested and are exercisable immediately.
    3. Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service.
    4. These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service.
    5. These Career Restricted Stock Units were issued to the Reporting Person in lieu of $123,000 in fees.
    6. This option to purchase 4,110 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 4,110 ordinary shares for $64.05 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.
    Remarks:
    /s/ John P. Ubbing, Authorized Representative under Power of Attorney 08/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $STE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    7/15/2025$276.00Equal-Weight → Overweight
    Morgan Stanley
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    More analyst ratings

    $STE
    SEC Filings

    View All

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    8/20/25 5:19:46 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    8/12/25 4:59:49 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    8/11/25 5:10:07 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STERIS Announces Chief Financial Officer Transition

    Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton,  Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Michael J. Tokich, Senior Vice President and Chief Financial Officer (CFO), is stepping down from his role following seventeen years as CFO. The transition from Tokich to Karen L. Burton, currently Vice President and Chief Accounting Officer (CAO), will occur on August 18, 2025. Thereafter, Tokich will become Senior Financial Advisor, reporting to the CEO. "Mike's contributions over the past 25 years at STERIS have been instrumental in our growth and success," said Dan Care

    8/6/25 4:31:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Financial Results for Fiscal 2026 First Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the first quarte

    8/6/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Raises Dividend to $0.63 per share

    DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company's 20th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H

    7/30/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Breeden Richard C exercised 4,110 units of Ordinary Shares at a strike of $64.05, increasing direct ownership by 13% to 36,664 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    8/15/25 4:31:11 PM ET
    $STE
    Industrial Specialties
    Health Care

    Director Sohi Mohsen exercised 4,110 units of Ordinary Shares at a strike of $64.05 and sold $994,456 worth of Ordinary Shares (4,110 units at $241.96) (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    8/12/25 5:28:02 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Shapiro Louis

    4 - STERIS plc (0001757898) (Issuer)

    8/12/25 5:27:39 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/13/24 5:14:05 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:49:03 AM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:32:52 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    View All

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    STERIS Announces Changes to Board of Directors

    David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

    5/11/21 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Financials

    Live finance-specific insights

    View All

    STERIS Announces Chief Financial Officer Transition

    Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton,  Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Michael J. Tokich, Senior Vice President and Chief Financial Officer (CFO), is stepping down from his role following seventeen years as CFO. The transition from Tokich to Karen L. Burton, currently Vice President and Chief Accounting Officer (CAO), will occur on August 18, 2025. Thereafter, Tokich will become Senior Financial Advisor, reporting to the CEO. "Mike's contributions over the past 25 years at STERIS have been instrumental in our growth and success," said Dan Care

    8/6/25 4:31:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Financial Results for Fiscal 2026 First Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the first quarte

    8/6/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Raises Dividend to $0.63 per share

    DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company's 20th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H

    7/30/25 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Steris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Steris from Equal-Weight to Overweight and set a new price target of $276.00

    7/15/25 8:30:16 AM ET
    $STE
    Industrial Specialties
    Health Care

    Jefferies initiated coverage on Steris with a new price target

    Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

    5/29/25 8:18:41 AM ET
    $STE
    Industrial Specialties
    Health Care

    Steris upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

    10/24/24 6:28:31 AM ET
    $STE
    Industrial Specialties
    Health Care